<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978728</url>
  </required_header>
  <id_info>
    <org_study_id>201811061RINC</org_study_id>
    <nct_id>NCT03978728</nct_id>
  </id_info>
  <brief_title>Analysis of Endotoxin Activity in Patients With ECMO</brief_title>
  <official_title>Analysis of Endotoxin Activity in Patients With Extracorporeal Membrane Oxygenation Life Support System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extra-corporeal membrane oxygenation (ECMO) can temporarily help patients gain time to wait&#xD;
      for cardiopulmonary recovery or further treatment in patients with cardiopulmonary failure.&#xD;
      Whether the blood flow provided by the ECMO can maintain the perfusion of various organs is&#xD;
      an important factor affecting survival. Some ECMO patients died after the complication of&#xD;
      sepsis. Our previous pilot analysis has recognized several ECMO patients with complicated&#xD;
      sepsis has high endotoxin activity level. Endotoxemia can also occur in heart surgery and&#xD;
      after cardiopulmonary bypass, trauma, organ transplantation, and out-of-hospital cardiac&#xD;
      arrest patients. These trials used endotoxin activity analysis (EAA, EAATM, Spectral&#xD;
      Diagnostics Inc., Canada) to analyze endotoxin activity. In addition, studies have indicated&#xD;
      that the combination of procalcitonin (PCT) concentration and EAA activity can improve the&#xD;
      accuracy of predicting sepsis. The primary aim of this study is to detect endotoxin activity&#xD;
      in patients with ECMO support and compare whether the prognosis was associated with different&#xD;
      level of EAA activity. The secondary aims are to analyze the risk factors leading to high EAA&#xD;
      activity and investigate the diagnostic value of septic shock combining PCT examination. We&#xD;
      suggest that the results of this study may help the ECMO medical team identify patients at&#xD;
      high risk for septic shock and conduct adequate managements to improve patient survival and&#xD;
      quality of life after survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Endotoxin activity level</measure>
    <time_frame>within 48 hours</time_frame>
    <description>Endotoxin activity level is measured by endotoxin activity analysis kit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endotoxin activity level</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Endotoxin activity level is measured by endotoxin activity analysis kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endotoxin activity level</measure>
    <time_frame>within 72 hours</time_frame>
    <description>Endotoxin activity level is measured by endotoxin activity analysis kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endotoxin activity level</measure>
    <time_frame>within 96 hours</time_frame>
    <description>Endotoxin activity level is measured by endotoxin activity analysis kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin level</measure>
    <time_frame>within 48 hours</time_frame>
    <description>Procalcitonin level in ECMO patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin C level</measure>
    <time_frame>within 48 hours</time_frame>
    <description>Cytatin C level in ECMO patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diamine oxidase level</measure>
    <time_frame>within 48 hours</time_frame>
    <description>Diamine oxidase level in ECMO patients</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiovascular Shock</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>ECMO patients</arm_group_label>
    <description>Patients with ECMO support</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extra-corporeal membrane oxygenation</intervention_name>
    <description>Cardiovascular shock patients received extra-corporeal membrane oxygenation suppot.</description>
    <arm_group_label>ECMO patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Paitents with extra-corporeal membrane oxygenation support&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with ECMO support&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 20 years old or &gt; 90 years old&#xD;
&#xD;
          -  not be able to collect blood sample within 48 hours after placement of ECMO&#xD;
&#xD;
          -  change plan to palliative care and plan to remove ECMO&#xD;
&#xD;
          -  non-native speakers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Chang Yeh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-Chang Yeh, MD, PhD</last_name>
    <phone>886-9-10513711</phone>
    <email>tonyyeh@ntuh.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Chang Yeh, M.D, Ph.D.</last_name>
      <phone>886-910513711</phone>
      <email>tonyyeh@ntuh.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 2, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

